Melatonin – Kodiac biolabs

Plain-language summaryIntrigue 65 / 100

Melatonin is the sleep hormone produced by the pineal gland in response to darkness. Supplementation is used for circadian rhythm disorders, jet lag, and sleep onset. The optimal dose is much lower than typically sold (0.3 mg, not 5-10 mg). Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

38/100

Canonical circadian probe with real evidence, but biologically settled and low on the novelty frontier

Look, melatonin is one of those compounds that scores well on evidence precisely because its research era is basically over. The MT1 and MT2 receptor pharmacology is fully mapped. The circadian phase-shifting literature goes back decades. Multiple well-designed RCTs confirm modest but real effects on sleep onset and jet lag. If you’re scoring “is there real data,” melatonin clears that bar handily. But that’s not what this rubric is asking.

The question is whether a serious bench scientist should be spending time here right now. And the honest answer for most investigators is no. The MT1/MT2 system is not an open frontier. The endogenous synthesis pathway from tryptophan through serotonin is textbook. The antioxidant angle gets mentioned in abstracts but the concentrations required for meaningful ROS scavenging in vivo are so far above physiological range that it doesn’t generate clean mechanistic insight. We’ve been down that road.

Where melatonin holds some residual bench value is as a reference ligand and timing tool for circadian entrainment experiments. If you’re studying chronobiology or trying to establish light-dark cycle baselines in rodent models, melatonin is what you reach for. Ramelteon is more selective at MT1/MT2, which makes it a sharper tool in some assay contexts, but melatonin’s endogenous status gives it ecological validity you dont get from a synthetic agonist. That’s a real but narrow argument for its continued utility.

The oncology literature is worth flagging as the one place where melatonin’s story isnt fully written. There’s a body of work, some of it multi-lab, pointing at adjunctive roles in solid tumor models, possibly through circadian disruption pathways. The Lissoni group’s clinical work from the 90s and 2000s is often cited but never quite confirmed at the scale or rigor you’d want. This is probably the most defensible reason a researcher might take a fresh look, but even here the signal hasn’t broken into mainstream oncology practice and the mechanism remains contested.

What we dont like: the gap between how widely this compound is discussed and how little genuinely open research territory remains. Most melatonin papers in 2025 are confirmatory or applied, not mechanistically generative. The pharmacokinetic variability at oral doses is real and relevant for study design, but it’s a methodological nuisance, not a scientific frontier. If your lab is doing circadian biology, keep a bottle on the shelf. If you’re looking for a research program, there are better places to build one.

Novelty: 18
Mechanism promise: 22
In-category differentiation: 35
Evidence quality: 62
Translational signal: 58
Research bench value: 52

Rationale Melatonin scores naturally low on novelty and mechanism because MT1/MT2 agonism and circadian phase-shifting are among the best-characterized pharmacology in all of chronobiology; evidence is actually solid by supplement standards, but the science is so settled it produces little frontier value for a bench investigator in 2026.

Endogenous indolamine hormone

An endogenous pineal hormone synthesized from serotonin, the master circadian regulator and a widely-used sleep supplement.

Abstract

Melatonin (N-acetyl-5-methoxytryptamine; CAS 73-31-4; molecular formula C13H16N2O2; molecular weight 232.28) is an endogenous indolamine synthesized in the pineal gland from serotonin via N-acetylation and 5-methoxylation. Endogenous melatonin secretion peaks during darkness and is the principal hormonal signal of biological night. Supplementation is widely used for sleep onset, jet lag, and shift work sleep. Mechanism is MT1 and MT2 melatonin receptor agonism; the compound also has direct antioxidant activity. Pharmacokinetics: plasma half-life 30 to 50 minutes; oral bioavailability variable (15 to 50 percent). Doses for sleep are 0.3 to 5 mg orally 30 to 60 minutes before bedtime; lower doses (0.3 to 1 mg) may be more physiologically appropriate but commercial supplements typically provide higher doses.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-149Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.